Xlife Sciences AG
XLS | SW
Overview
Corporate Details
- ISIN(s):
- CH0461929603 (+1 more)
- LEI:
- 984500AH590BE88BB517
- Country:
- Switzerland
- Address:
- Talacker 35, 8001 Zürich
- Sector:
- Health Care
- Industry:
- Pharmaceuticals
Description
We bring selected projects in the four areas of technology platforms, biotechnologies/therapies, medical technology (health technology), and artificial intelligence in the life science sector and digital health to the next stage of development.We lead these projects from the very beginning after an invention has been made and typically commercialize them after two to three years by, e.g., a trade sale, by entering into a joint venture with an industrial partner or by outlicensing patents. For the identification, selection and development of our projects, we benefit from our growing network with universities, clinical centers and research institutions.Typically, we incorporate a separate Portfolio company for each project. Currently, we have a portfolio of 22 Portfolio Companies, in which we hold at least a minority stake. More information about these Portfolio Companies can be found here.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-06-24 18:00 |
Declaration of Voting Results & Voting Rights Announcements
Xlife Sciences AG: Successful General Meeting and Growth Prospects for 2025
|
English | 6.1 KB | |
| 2025-06-24 02:00 |
AGM Report
Xlife Sciences AG: Successful General Meeting and Growth Prospects for 2025
|
English | 8.2 KB | |
| 2025-06-24 02:00 |
Declaration of Voting Results & Voting Rights Announcements
Xlife Sciences AG: Erfolgreiche Generalversammlung und Wachstumsaussichten in 2…
|
German | 8.5 KB | |
| 2025-06-16 16:00 |
Regulatory News Service
Strategic Collaboration Between Xlife Sciences AG, Huraypositive Corp., and Onc…
|
English | 9.8 KB | |
| 2025-06-16 02:00 |
Regulatory News Service
Strategic Collaboration Between Xlife Sciences AG, Huraypositive Corp., and Onc…
|
English | 12.3 KB | |
| 2025-06-16 02:00 |
Regulatory News Service
Strategische Zusammenarbeit zwischen Xlife Sciences AG, Huraypositive Corp. und…
|
German | 13.4 KB | |
| 2025-06-13 17:42 |
Regulatory News Service
Strategic Alliance Between Xlife Sciences AG, JIPYONG LLC and JIPYONG IP to Acc…
|
English | 9.0 KB | |
| 2025-06-13 02:00 |
Regulatory News Service
Strategic Alliance Between Xlife Sciences AG, JIPYONG LLC and JIPYONG IP to Acc…
|
English | 11.4 KB | |
| 2025-06-13 02:00 |
Regulatory News Service
Strategische Allianz zwischen Xlife Sciences AG, JIPYONG LLC und JIPYONG IP sol…
|
German | 12.9 KB | |
| 2025-05-07 07:00 |
Regulatory News Service
Xlife Sciences AG Announces Strategic Collaboration between Portfolio Company F…
|
English | 9.9 KB | |
| 2025-05-05 07:00 |
Regulatory News Service
Xlife Sciences AG confirms sustainable value development and strategic scaling …
|
English | 5.4 KB | |
| 2025-04-25 07:00 |
Earnings Release
Xlife Sciences AG publishes 2024 Annual Report: Strategic Expansion, Technologi…
|
English | 7.2 KB | |
| 2025-04-23 07:00 |
Regulatory News Service
From Lab to Unicorn: Xlife Sciences AG Portfolio Company VERAXA Biotech AG to m…
|
English | 7.3 KB | |
| 2024-12-24 18:35 |
Regulatory News Service
Xlife Sciences AG Announces Potential Acquisition of Portfolio Company FUSE-AI …
|
English | 8.3 KB | |
| 2024-12-23 18:35 |
Regulatory News Service
Xlife Sciences AG Announces Potential Acquisition of Portfolio Company FUSE-AI …
|
English | 8.3 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2022-01-24 | Grace Beteiligungs GmbH | Close relation | Buy | None | 57,537.30 EUR |
| 2022-01-24 | Pfleger, Christian | Board | Buy | None | 36,800.00 EUR |
| 2022-01-24 | Wild, Daniel | Supervisory board | Buy | None | 5,658.16 EUR |
| 2022-01-24 | Pfleger, Christian | Board | Buy | None | 18,480.00 EUR |
| 2022-01-22 | Horch, Johann | Board | Buy | None | 1,210.61 EUR |
| 2022-01-21 | Baumann, Oliver R. | Board | Buy | None | 21,500.00 EUR |
| 2022-01-19 | Baumann, Oliver R. | Board | Buy | None | 27,000.00 EUR |
| 2022-01-14 | Baumann, Oliver R. | Board | Buy | None | 22,935.20 EUR |
| 2021-12-20 | Baumann, Oliver R. | Board | Buy | None | 13,625.00 EUR |
| 2021-12-17 | Engels Consulting & Investment GmbH | Close relation | Sell | None | 22,500.00 EUR |
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
ABIVAX | France | ABVX | |
|
Addex Therapeutics Ltd | Switzerland | ADXN | |
|
AegirBio AB | Sweden | AEGIR | |
|
AGRONOMICS LIMITED | Isle of Man | ANIC | |
|
AIREA PLC | United Kingdom | AIEA | |
|
Alkaloid AD | North Macedonia | ALK | |
| Alma Yesodot Ltd. | Israel | KVSR | ||
|
Amphastar Pharmaceuticals Inc. | United States of America | AMPH | |
| Ananda Pharma Plc | United Kingdom | N/A | ||
|
Antibiotice S.A. | Romania | ATB |